Trials / Completed
CompletedNCT04791852
Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 94 (actual)
- Sponsor
- Puerta de Hierro University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography \> 1 year after HT. Our main goal is to evaluate the performance of Donor-derived Cell Free DNA (ddcf-DNA) as a biomarker of CAV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Donor-derived Cell Free DNA | We will compare ddcfDNA with coronary angiogram determined CAV grading, according to ISHTL2010 classification |
Timeline
- Start date
- 2019-01-10
- Primary completion
- 2021-01-31
- Completion
- 2021-04-15
- First posted
- 2021-03-10
- Last updated
- 2021-09-16
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04791852. Inclusion in this directory is not an endorsement.